Furthermore, preclinical studies demonstrated that SGLT2 inhibitors block the functioning of the Na+/H+ exchanger [128], an integral membrane protein that is upregulated in heart failure and that was linked to arrhythmogenesis and increased ROS production [129,130,131]. This evidence concerns the gene SLC5A2 and heart failure.